vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and Velo3D, Inc. (VELO). Click either name above to swap in a different company.
Velo3D, Inc. is the larger business by last-quarter revenue ($9.4M vs $9.1M, roughly 1.0× Protalix BioTherapeutics, Inc.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -231.9%, a 171.6% gap on every dollar of revenue. On growth, Velo3D, Inc. posted the faster year-over-year revenue change (-25.2% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-8.3M). Over the past eight quarters, Velo3D, Inc.'s revenue compounded faster (-1.8% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Velo3D, Inc. develops and sells advanced end-to-end metal additive manufacturing (3D printing) solutions, comprising industrial-grade printers, specialized processing software, and high-performance metal materials. It primarily serves global aerospace, defense, energy, semiconductor and industrial manufacturing markets, enabling customers to produce complex, high-precision metal parts that are difficult to manufacture with traditional methods.
PLX vs VELO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $9.4M |
| Net Profit | $-5.5M | $-21.9M |
| Gross Margin | 49.4% | -73.6% |
| Operating Margin | -51.1% | -231.0% |
| Net Margin | -60.3% | -231.9% |
| Revenue YoY | -49.9% | -25.2% |
| Net Profit YoY | -184.8% | -2.9% |
| EPS (diluted) | $-0.06 | $-0.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $9.4M | ||
| Q3 25 | $17.9M | $13.6M | ||
| Q2 25 | $15.7M | $13.6M | ||
| Q1 25 | $10.1M | $9.3M | ||
| Q4 24 | $18.2M | $12.6M | ||
| Q3 24 | $18.0M | $8.2M | ||
| Q2 24 | $13.5M | $10.3M | ||
| Q1 24 | — | $9.8M |
| Q4 25 | $-5.5M | $-21.9M | ||
| Q3 25 | $2.4M | $-11.2M | ||
| Q2 25 | $164.0K | $-13.3M | ||
| Q1 25 | $-3.6M | $-25.0M | ||
| Q4 24 | $6.5M | $-21.3M | ||
| Q3 24 | $3.2M | $-21.9M | ||
| Q2 24 | $-2.2M | $935.0K | ||
| Q1 24 | — | $-27.5M |
| Q4 25 | 49.4% | -73.6% | ||
| Q3 25 | 53.4% | 3.2% | ||
| Q2 25 | 62.5% | -11.7% | ||
| Q1 25 | 19.1% | 7.5% | ||
| Q4 24 | 78.7% | -3.5% | ||
| Q3 24 | 53.4% | 49.4% | ||
| Q2 24 | 29.8% | -28.0% | ||
| Q1 24 | — | -28.8% |
| Q4 25 | -51.1% | -231.0% | ||
| Q3 25 | 11.9% | -73.3% | ||
| Q2 25 | 7.5% | -85.4% | ||
| Q1 25 | -41.0% | -123.6% | ||
| Q4 24 | 39.6% | -167.0% | ||
| Q3 24 | 22.2% | -213.8% | ||
| Q2 24 | -18.0% | -187.7% | ||
| Q1 24 | — | -211.1% |
| Q4 25 | -60.3% | -231.9% | ||
| Q3 25 | 13.2% | -82.0% | ||
| Q2 25 | 1.0% | -97.7% | ||
| Q1 25 | -35.8% | -268.4% | ||
| Q4 24 | 35.6% | -168.5% | ||
| Q3 24 | 18.0% | -265.3% | ||
| Q2 24 | -16.4% | 9.0% | ||
| Q1 24 | — | -281.2% |
| Q4 25 | $-0.06 | $-0.87 | ||
| Q3 25 | $0.03 | $-0.65 | ||
| Q2 25 | $0.00 | $-0.94 | ||
| Q1 25 | $-0.05 | $-1.87 | ||
| Q4 24 | $0.10 | $7.06 | ||
| Q3 24 | $0.03 | $-35.52 | ||
| Q2 24 | $-0.03 | $1.65 | ||
| Q1 24 | — | $-55.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $39.0M |
| Total DebtLower is stronger | — | $31.0M |
| Stockholders' EquityBook value | $48.2M | $38.2M |
| Total Assets | $82.3M | $105.3M |
| Debt / EquityLower = less leverage | — | 0.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $39.0M | ||
| Q3 25 | $13.6M | $11.8M | ||
| Q2 25 | $17.9M | $854.0K | ||
| Q1 25 | $19.5M | $3.9M | ||
| Q4 24 | $19.8M | $1.2M | ||
| Q3 24 | $27.4M | $1.6M | ||
| Q2 24 | $23.4M | $3.2M | ||
| Q1 24 | — | $10.9M |
| Q4 25 | — | $31.0M | ||
| Q3 25 | — | $23.0M | ||
| Q2 25 | — | $22.5M | ||
| Q1 25 | — | $21.7M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | — | $32.3M | ||
| Q2 24 | — | $33.5M | ||
| Q1 24 | — | $44.0M |
| Q4 25 | $48.2M | $38.2M | ||
| Q3 25 | $52.9M | $29.9M | ||
| Q2 25 | $49.9M | $21.4M | ||
| Q1 25 | $45.2M | $32.8M | ||
| Q4 24 | $43.2M | $39.7M | ||
| Q3 24 | $32.4M | $34.4M | ||
| Q2 24 | $28.6M | $52.1M | ||
| Q1 24 | — | $45.5M |
| Q4 25 | $82.3M | $105.3M | ||
| Q3 25 | $82.3M | $93.7M | ||
| Q2 25 | $78.5M | $78.4M | ||
| Q1 25 | $73.9M | $91.3M | ||
| Q4 24 | $73.4M | $89.2M | ||
| Q3 24 | $61.6M | $110.8M | ||
| Q2 24 | $91.5M | $116.7M | ||
| Q1 24 | — | $136.1M |
| Q4 25 | — | 0.81× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 1.05× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.94× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-7.7M |
| Free Cash FlowOCF − Capex | $1.6M | $-8.3M |
| FCF MarginFCF / Revenue | 17.8% | -88.3% |
| Capex IntensityCapex / Revenue | 4.4% | 6.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-7.7M | ||
| Q3 25 | $-3.7M | $-6.0M | ||
| Q2 25 | $-5.2M | $-1.2M | ||
| Q1 25 | $-5.1M | $-12.3M | ||
| Q4 24 | $4.0M | $-2.2M | ||
| Q3 24 | $4.1M | $-2.0M | ||
| Q2 24 | $-3.6M | $-8.0M | ||
| Q1 24 | — | $-20.5M |
| Q4 25 | $1.6M | $-8.3M | ||
| Q3 25 | $-4.2M | $-6.3M | ||
| Q2 25 | $-5.7M | $-3.0M | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $3.6M | $-2.2M | ||
| Q3 24 | $4.0M | $-2.0M | ||
| Q2 24 | $-3.8M | $-8.0M | ||
| Q1 24 | — | $-20.5M |
| Q4 25 | 17.8% | -88.3% | ||
| Q3 25 | -23.7% | -46.5% | ||
| Q2 25 | -36.2% | -22.2% | ||
| Q1 25 | -53.0% | — | ||
| Q4 24 | 19.6% | -17.7% | ||
| Q3 24 | 22.4% | -24.2% | ||
| Q2 24 | -28.1% | -77.1% | ||
| Q1 24 | — | -209.8% |
| Q4 25 | 4.4% | 6.4% | ||
| Q3 25 | 2.8% | 2.3% | ||
| Q2 25 | 2.8% | 13.3% | ||
| Q1 25 | 3.0% | 0.0% | ||
| Q4 24 | 2.3% | 0.2% | ||
| Q3 24 | 0.5% | 0.2% | ||
| Q2 24 | 1.3% | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | -8.52× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
VELO
Segment breakdown not available.
